Showing results (161-170 of 203) with videos related to
Sort By:
Pageof 21
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|February 8, 2022
Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig modelLukas Christian Sebeke, Juan Daniel Castillo Gómez, Edwin Heijman, et al.Cancers|November 11, 2022
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV TrialViktor Grünwald, Daniel Pink, Gerlinde Egerer, et al.Journal of Cancer Research and Clinical Oncology|January 8, 2026
Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysisMichael Hoberger, Romy L Zuber, Anton Burkhard-Meier, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2026
Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and DosimetryLisa Glantschnig, Johanna S Enke, Bradley W Schuller, et al.Oncology and Therapy|June 5, 2026
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort StudyMichael Hoberger, Dorit Di Gioia, Romy L Zuber, et al.Cancer|June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance surveyNathalie Rippinger, Christine Fischer, Markus W Haun, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.Der Pathologe|December 1, 2020
[Diagnosis and therapy of tumors with NTRK gene fusion]Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, et al.Pageof 21